Communiqués Shanghai Henlius Biotech, Inc.

Actions

2696

CNE100003N76

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:35 22/05/2024			Varia. 5j.	Varia. 1 janv.
18,84 ^HKD	+4,67 %		-.--%	+35,54 %

24/05	La demande d'autorisation de mise sur le marché de Henlius pour un biosimilaire du Denosumab est acceptée et validée par l'autorité de régulation	MT
24/05	Shanghai Henlius Biotech, Inc. et Organon annoncent que l'Agence européenne des médicaments a validé les demandes d'autorisation de mise sur le marché (AMM) du Hlx14	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Alligator Bioscience’s Announces Henlius Biotech has Received FDA IND Clearance for Phase 3 Initiation to Evaluate HLX22 (AC101) in 1st Line HER2+ Advanced Gastric Cancer	21/05	AQ
Triple Negative Breast Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	14/05	AQ
Henlius maintained a positive momentum of development in Q1 2024, with impressive performances by core products	30/04	AQ
Shanghai Henlius Biotech, Inc. - IND Application for the Clinical Trial of Novel Anti-TIGIT Fc Fusion Protein HLX53 in Combination with HANSIZHUANG Plus HANBEITAI Approved by NMPA	18/04	AQ
Henlius Releases 2023 ESG Report: Pursuing Sustainable Development with Patient-centricity	17/04	PR
Henlius Forecasts Profit in 2023: Achieving first full year of profitability, and ushering in a new phase of high-quality development	04/03	PR
Henlius Adalimumab Biosimilar Received sNDA Acceptance Notification from the NMPA	01/03	AQ
Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene	12/01	AQ
Triple Negative Breast Cancer Pipeline, FDA Approvals, Clinical Trials Assessment, Companies 2023 \| Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., and others.	05/12	AQ
Henlius Xuhui Facility Passes Colombian GMP Inspection for HANLIKANG	29/11	AQ
Anaplastic Thyroid Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	23/11	AQ
Henlius Deepens Collaboration with Intas to bring Henlius Novel anti-PD-1 mAb Serplulimab to Europe and India	30/10/23	AQ
Henlius Announces NMPA Approvals of Two ADC Candidates for IND	30/10/23	AQ
Shanghai Henlius Biotech, Inc. - First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe	26/10/23	AQ
Henlius Biotech, Inc. - Results from the Preclinical Study of HLX43, a Potential FIC PD-L1-Targeting ADC Released at 2023 ESMO	25/10/23	AQ
Henlius Xuhui Facility Passes PIC/S Member ANVISA GMP Inspection for HANLIKANG and HANQUYOU	23/10/23	AQ
Henlius Xuhui Facility Passes GMP Inspection for HANSIZHUANG by PIC/S Member BPOM	12/10/23	AQ
Henlius Novel Anti-PD-1 mAb HANSIZHUANG approved for the Treatment of ESCC	25/09/23	AQ
Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius novel anti-PD-1 mAb HANSIZHUANG in MENA	13/09/23	AQ
Henlius Biotech, Inc. - HANQUYOU Marks 3rd Anniversary with Brilliant Achievements	28/07/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Shanghai Henlius Biotech, Inc.

Actions

2696

CNE100003N76

Communiqués

Filtres